new glp-1 medications A wave of weight-loss therapies aims to be better than today's GLP-1s Eli Lilly to seek approval

Loss of muscle mass and nutritional deficiencies can be avoided with a focused, high-protein meal plan, workout plan, and regular health and fitness testing

In fact, in one long-term commitment

[PMC free article: PMC6724526] [PubMed: 31479145] 217

This therapy is personalised and provider-directed

Mike Haney: And what do we know about the sort of implications of long-term use of this

DNA Cell Biol 37:10311043 Wu X, Li S, Xue P, Li Y (2017) Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin